MétaCan
Menu
← Back to cohort
Record W4210339934 · doi:10.1002/alz.057701

Insights on FTD: An externally led patient‐focused drug development meeting

2021· article· en· W4210339934 on OpenAlexaboutno aff
Debra Niehoff, Shana G Dodge, Elizabeth Graham, Megan S. Barker, Stephanie Cosentino, Dianna KH Wheaton, Sharon Denny, Penny A. Dacks, Susan Dickinson

Bibliographic record

VenueAlzheimer s & Dementia · 2021
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsCorticobasal degenerationPrimary progressive aphasiaDiseaseProgressive supranuclear palsyFrontotemporal dementiaPsychologyMedicinePsychiatryDrug developmentInterpersonal communicationClinical psychologyDrug

Abstract

fetched live from OpenAlex

Abstract Background Understanding the lived experience of those affected by a disorder should be central to the development and evaluation of therapeutics. Disease‐specific Externally Led Patient‐Focused Drug Development (EL‐PFDD) meetings were established by the FDA to hear directly from those living with a condition about experiences, symptoms, treatments, and hopes for new therapies. Such insights are particularly important for frontotemporal degeneration (FTD), a genetically and clinically heterogenous condition that includes behavioral variant FTD (bvFTD), primary progressive aphasias, progressive supranuclear palsy, corticobasal syndrome, and ALS with FTD. Method On March 5, 2021, AFTD hosted an EL‐PFDD for FTD; 382 caregivers, family members, and persons with FTD participated, plus 171 professionals. In preparation, AFTD and the FTD Disorders Registry conducted the FTD Insights Survey, gathering information on clinical and genetic characteristics of respondents; the earliest, current, and most concerning symptoms; and perspectives on treatments and clinical trials. 1,237 persons with FTD, care partners/caregivers, and family members in the US, Canada and UK had completed the survey by October 31, 2020. Result People living with all FTD syndromes described challenges in activities of daily life, including preparing meals, managing finances, driving, and conversing. Symptoms vary within and across disorders, encompassing language, motor function, thinking/decision‐making, interpersonal/emotional functioning, among others. Many people diagnosed have limited awareness of their symptoms (65% bvFTD; 37% other FTD disorders). In genetic FTD, the path to diagnosis can be simpler, yet a lifetime of perceived or known risk can dramatically influence life decisions. The lack of effective, approved therapies – disease‐modifying or symptomatic – was a universal concern. Non‐prescription and off‐label prescription therapies may stabilize symptoms temporarily while prescribed acetylcholinesterase inhibitors can exacerbate symptoms. Many people are willing to participate in clinical research depending on illness stage and burden imposed by trial design. Conclusion The community of those affected by FTD offers insights into this condition as partners in research. Central themes of the EL‐PFDD meeting for FTD will be summarized by AFTD in a Voice of the Patient reported submitted to the FDA. Results of the FTD Insights Survey are available to researchers through the FTD Disorders Registry.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Qualitative · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.015
Threshold uncertainty score0.051

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.013
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.000
Science and technology studies0.0030.001
Scholarly communication0.0020.002
Open science0.0010.008
Research integrity0.0030.005
Insufficient payload (model declined to judge)0.0150.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.261
Teacher spread0.237 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designQualitative
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→